Research Paper Volume 11, Issue 18 pp 7357—7385

Figure 3. miR-375-3p suppresses tumorigenesis and reverses chemoresistance with 5FU of CRC in vivo. (A) Schematic outline of the treatment of HCT116 cells transfected with antagomiR-375-3p/NC in a subcutaneous tumor model followed by intratumoral injection of antagomiR-375-3p/NC. (B) qRT-PCR analysis of miR-375-3p expression in mice xenograft of antagomiR-375-3p/NC groups. (C) Representative images of transplanted tumors removed from mice after sacrifice at the 36^th day, tumor volume and tumor weight were measured. (D) Representative images of hematoxylin and eosin (H&E) staining and Ki67 immunostaining of tumor lumps from two groups. Scale bar=50μm. (E) Schematic outline of the treatment of HCT116/FU cells transfected with agomiR-375-3p/NC in a subcutaneous tumor model followed by intratumoral injection of agomiR-375-3p/NC or PBS/5FU. (F) qRT-PCR analysis of miR-375-3p expression in mice xenograft of agomiR-375-3p/NC groups. (G) Representative images of transplanted tumors removed from mice after sacrifice at the 27^th day, tumor volume and tumor weight were measured. (H) Representative images of hematoxylin and eosin (H&E) staining and Ki67 immunostaining of tumor lumps from 4 different groups. *P < 0.05, ** P < 0.01 and *** P < 0.001.